Patents Assigned to Daiichi Sankyo Company, Limited
  • Publication number: 20240190961
    Abstract: Provided is a pharmaceutical composition for use in the treatment or prevention of cancer, etc. The present invention provides a pharmaceutical composition or a method for treating cancer, wherein an anti-GARP antibody and an immunomodulator are administered in combination.
    Type: Application
    Filed: October 23, 2020
    Publication date: June 13, 2024
    Applicant: DAIICHI SANKYO COMPANY, LIMITED
    Inventors: Shinko HAYASHI, Saori ISHIDA, Kazuki SATOH, Masato HATA
  • Patent number: 12006372
    Abstract: The present invention relates to an antibody that binds to GARP and is useful as a therapeutic agent for a tumor, and a method for treating a tumor using the aforementioned antibody. It is an object of the present invention to provide an antibody, which inhibits the function of Treg in a tumor and is thereby used as a pharmaceutical product having therapeutic effects, a method for treating a tumor using the aforementioned antibody, and the like. An anti-GARP antibody that binds to GARP and exhibits inhibitory activity to Treg function and exhibits ADCC activity is obtained, and moreover a pharmaceutical composition for use in tumor therapy, comprising the aforementioned antibody, etc. is obtained.
    Type: Grant
    Filed: June 28, 2021
    Date of Patent: June 11, 2024
    Assignee: DAIICHI SANKYO COMPANY, LIMITED
    Inventors: Kazuki Satoh, Kazuki Hirahara, Ichiro Watanabe, Masato Amano
  • Publication number: 20240182569
    Abstract: To provide a stable bispecific molecule. A Fab that specifically binds to CD3, the Fab comprising the following CDRH1 to 3 and CDRL1 to 3: CDRH1 consisting of the amino acid sequence represented by SEQ ID NO: 32; CDRH2 consisting of the amino acid sequence represented by SEQ ID NO: 33; CDRH3 consisting of the amino acid sequence represented by SEQ ID NO: 34; CDRL1 consisting of the amino acid sequence represented by SEQ ID NO: 35; CDRL2 consisting of the amino acid sequence represented by SEQ ID NO: 36; and CDRL3 consisting of the amino acid sequence represented by SEQ ID NO: 37.
    Type: Application
    Filed: March 28, 2022
    Publication date: June 6, 2024
    Applicant: DAIICHI SANKYO COMPANY, LIMITED
    Inventors: Makiko NAKAYAMA, Kensuke NAKAMURA, Shinji FURUZONO, Ryota MATSUMOTO
  • Patent number: 11999724
    Abstract: The present invention relates to a novel method for producing diarylpyridine derivatives, and the object of the present invention is to provide a novel, industrially useful method. The present inventors developed a novel method for synthesizing pyridine rings without using palladium, a strong base, or a high-temperature reaction. In particular, they successfully developed a method that can be used to synthesize iminium salts as intermediates, synthesize cyano compounds from these iminium salts, and cyclize the cyano compounds into pyridines under very mild reaction conditions.
    Type: Grant
    Filed: July 3, 2019
    Date of Patent: June 4, 2024
    Assignee: Daiichi Sankyo Company, Limited
    Inventors: Yuichi Aki, Fumihiko Toriyama, Natsuki Sakurai, Ai Kameda, Tomokazu Ogura
  • Patent number: 11993593
    Abstract: The present invention addresses the problem of providing a compound for prophylaxis and/or treatment of central inflammatory diseases, or a pharmacologically acceptable salt thereof. The present invention addresses a compound of a general formula (I) or a pharmacologically acceptable salt thereof as a means to solve the problem. [R1: a C1-C6 alkyl group or the like, R2: a C1-C6 alkyl group or the like, A: a 5-membered aromatic hetero-ring or the like, R3, R3?: a C1-C6 alkyl group or the like].
    Type: Grant
    Filed: June 21, 2022
    Date of Patent: May 28, 2024
    Assignee: Daiichi Sankyo Company, Limited
    Inventors: Keiji Saito, Katsuyoshi Nakajima, Yasuyuki Ogawa, Mitsuhiro Makino, Kaori Ito, Seiko Nagata, Makoto Hirasawa
  • Patent number: 11981686
    Abstract: An object of the present invention is to provide a compound that has a specific chemical structure having an activation effect on SIRT6 and is useful as an active component for preventing and treating inflammatory diseases, and the present invention relates to a compound represented by Formula (1) or a pharmaceutically acceptable salt thereof, where each symbol in Formula (1) has the same definition as that described in the specification.
    Type: Grant
    Filed: January 23, 2020
    Date of Patent: May 14, 2024
    Assignee: DAIICHI SANKYO COMPANY, LIMITED
    Inventors: Junya Kawai, Osamu Iwamoto, Yuma Umezaki, Katsuyoshi Nakajima, Hiroyuki Tsuruoka, Keiji Saito, Nobuya Kurikawa, Natsumi Nishihama, Shinji Tanaka, Momoko Ogitani, Tomohiro Honda, Wataru Saitoh, Tsuyoshi Soneda, Nobuyuki Ohkawa
  • Publication number: 20240150309
    Abstract: An object of the present invention is to provide a compound having an anti-inflammatory activity or a pharmacologically acceptable salt thereof. The solution of the present invention is a compound of general formula (1) or a pharmacologically acceptable salt thereof. wherein the symbols in the formula are defined below: R1: e.g., a C1-C6 alkyl group; R2: a C1-C6 alkyl group; A: e.g., an oxygen atom; and R3: e.g., a C1-C6 alkyl group.
    Type: Application
    Filed: November 3, 2023
    Publication date: May 9, 2024
    Applicant: Daiichi Sankyo Company, Limited
    Inventors: Keiji Saito, Katsuyoshi Nakajima, Toru Taniguchi, Osamu Iwamoto, Satoshi Shibuya, Yasuyuki Ogawa, Kazumasa Aoki, Nobuya Kurikawa, Shinji Tanaka, Momoko Ogitani, Eriko Kioi, Kaori Ito, Natsumi Nishihama, Tsuyoshi Mikkaichi, Wataru Saitoh
  • Publication number: 20240150390
    Abstract: The purpose of the present invention is to provide a novel stereoselective method for preparing a cyclic dinucleotide derivative and a production intermediate therefor, which can be used for an antibody-immunostimulant conjugate. Also provided is a method for producing a cyclic dinucleotide-linker and an antibody-immunostimulant conjugate while using the above production method. Further provided is a method for preparing a cyclic dinucleotide derivative, the method including the step of subjecting a compound (I) and a compound (IV) to stereoselective condensation using an optically active phosphitylating agent (Rc-II) or (Sc-II).
    Type: Application
    Filed: January 31, 2022
    Publication date: May 9, 2024
    Applicant: Daiichi Sankyo Company, Limited
    Inventors: Tomokazu OGURA, Takeshi NAKAYA, Hidekazu INOUE, Narumi ABE, Yuzo ABE, Tatsuya NAKAMURA, Yuko YAMAMOTO, Kohei SAKANISHI, Tatsuhiro SAKAMOTO, Satoshi NAKANE
  • Publication number: 20240150472
    Abstract: The present invention provides a chimeric polypeptide receptor in which an extracellular region comprising an antigenic region capable of being bound by an anti-human nicotinic acetylcholine receptor ?1 subunit (nAChR?1) antibody, a transmembrane region, and an intracellular domain comprising an intracellular signaling domain are arranged in the presented order from the N-terminus towards the C-terminus, wherein an amino acid sequence of the antigenic region comprises the amino acid sequence as set forth in SEQ ID NO: 2 or an amino acid sequence derived from the amino acid sequence as set forth in SEQ ID NO: 2 by the substitution, deletion, insertion, and/or addition of one or several amino acids, a polynucleotide encoding the chimeric polypeptide receptor polypeptide, a cell expressing the chimeric polypeptide receptor, etc., which are useful in the treatment of myasthenia gravis.
    Type: Application
    Filed: March 16, 2022
    Publication date: May 9, 2024
    Applicant: Daiichi Sankyo Company, Limited
    Inventors: Kazunori Yoshikiyo, Kazumichi Goto, Maki Tsujimoto, Chikako Nagasaki, Sayaka Yoshida, Hiroaki Tagaya
  • Publication number: 20240139134
    Abstract: An object of the present invention is to provide a medicine that can simply treat and/or prevent a retinal degenerative disease associated with photoreceptor degeneration, including retinitis pigmentosa. The solution is to provide an agent for treating and/or preventing a retinal degenerative disease associated with photoreceptor degeneration, containing a compound having a retinoic acid receptor agonistic activity (for example, tamibarotene, tamibarotene methyl ester, tamibarotene ethyl ester, tazarotene, tazarotenic acid, adapalene, palovarotene, retinol, isotretinoin, alitretinoin, etretinate, acitretin or bexarotene) or a salt thereof.
    Type: Application
    Filed: December 21, 2023
    Publication date: May 2, 2024
    Applicant: Daiichi Sankyo Company, Limited
    Inventors: Naoki Tsuji, Masumi Ueno
  • Patent number: 11963974
    Abstract: The present invention provides a novel antisense oligonucleotide and a composition for preventing or treating glycogen storage disease type Ia. The present invention provides an antisense oligonucleotide which hybridizes with a pre-mRNA sequence derived from a region including at least one of a base at position 42911000, a base at position 42911004, and a base at position 42911005 in a base sequence of human chromosome 17 of GRCh38/hg38 and has activity to inhibit aberrant splicing of pre-mRNA of c.648G>T variant G6PC.
    Type: Grant
    Filed: March 9, 2018
    Date of Patent: April 23, 2024
    Assignees: NATIONAL CENTER FOR CHILD HEALTH AND DEVELOPMENT, HIROSHIMA UNIVERSITY, DAIICHI SANKYO COMPANY, LIMITED
    Inventors: Go Tajima, Satoshi Okada, Miyuki Tsumura
  • Patent number: 11958878
    Abstract: The present invention establishes a molecular therapy for glycogen storage disease type Ia. The present invention provides an oligonucleotide of 15-30 bases comprising a nucleotide sequence complementary to die cDNA of G6PC gene with c.648G>T mutation, wherein the oligonucleotide comprises a sequence complementary to a region comprising any site between the 82nd to the 92nd nucleotide from the 5? end of exon 5 of the G6PC gene with c.648C>T mutation, a pharmacologically acceptable salt or solvate thereof. Also provided is a pharmaceutical drug comprising the oligonucleotide, a pharmacologically acceptable salt or solvate thereof (e.g., therapeutic drug for glycogen storage disease type Ia).
    Type: Grant
    Filed: March 5, 2019
    Date of Patent: April 16, 2024
    Assignees: Daiichi Sankyo Company, Limited, Kobe Gakuin Educational Foundation
    Inventors: Makoto Koizumi, Yoshiyuki Onishi, Takeshi Masuda, Mitsuhiro Iwamoto, Yukiko Sekiguchi, Kentaro Ito, Shinnosuke Tsuji, Masafumi Matsuo
  • Publication number: 20240115720
    Abstract: The present invention provides a novel anti-DLL3 antibody-pyrrolodiazepine derivative and a novel anti-DLL3 anti-body-pyrrolodiazepine derivative conjugate using the same.
    Type: Application
    Filed: January 13, 2022
    Publication date: April 11, 2024
    Applicants: MEMORIAL SLOAN KETTERING CANCER CENTER, TRI-INSTITUTIONAL THERAPEUTICS DISCOVERY INSTITUTE, DAIICHI SANKYO COMPANY, LIMITED
    Inventors: John T. POIRIER, Charles RUDIN, Jason LEWIS, Abdul KHAN, David ANDREW, Xinlei CHEN, Ivo LORENZ, Hironori MATSUNAGA
  • Publication number: 20240115721
    Abstract: It is an object of the present invention to provide an antibody-drug conjugate of an antibody binding to DLL3 and a drug having antitumor activity, a pharmaceutical composition comprising the antibody-drug conjugate and having therapeutic effects on a tumor, a method for treating a tumor using the antibody-drug conjugate or the pharmaceutical composition, and the like. The present invention provides an antibody-drug conjugate of an antibody binding to DLL3 and a drug having antitumor activity, a pharmaceutical composition comprising the antibody or the antibody-drug conjugate, and a method for treating a tumor.
    Type: Application
    Filed: January 13, 2022
    Publication date: April 11, 2024
    Applicants: MEMORIAL SLOAN KETTERING CANCER CENTER, TRI-INSTITUTIONAL THERAPEUTICS DISCOVERY INSTITUTE, DAIICHI SANKYO COMPANY, LIMITED
    Inventors: John T. POIRIER, Charles RUDIN, Jason LEWIS, Abdul KHAN, David ANDREW, Xinlei CHEN, Ivo LORENZ, Hironori MATSUNAGA
  • Patent number: 11952423
    Abstract: A novel antibody that can be used as an anti-tumor agent and an anti-tumor agent that comprises, as an active ingredient, a molecule containing such an antibody.
    Type: Grant
    Filed: May 16, 2023
    Date of Patent: April 9, 2024
    Assignees: MIE UNIVERSITY, DAIICHI SANKYO COMPANY, LIMITED
    Inventors: Hiroshi Shiku, Yasushi Akahori, Kento Tanaka, Ayaka Yatsu, Junya Ichikawa, Toshiaki Ohtsuka, Shiho Kozuma, Ryuji Hashimoto, Makiko Nakayama, Naoya Shinozaki, Kensuke Nakamura, Ichiro Watanabe, Shinji Furuzono
  • Patent number: 11945882
    Abstract: Crystals of the compound represented by formula (1), a method for the production thereof, and a method for producing an antibody-drug conjugate using the crystals.
    Type: Grant
    Filed: August 30, 2018
    Date of Patent: April 2, 2024
    Assignee: DAIICHI SANKYO COMPANY, LIMITED
    Inventors: Tatsuya Yamaguchi, Takashi Kouko, Shigeru Noguchi, Yohei Yamane, Fumikatsu Kondo, Takahiro Aoki, Tadahiro Takeda, Kohei Sakanishi, Hitoshi Sato, Tsuyoshi Ueda, Shinji Matuura, Kei Kurahashi, Yutaka Kitagawa, Tatsuya Nakamura
  • Publication number: 20240093227
    Abstract: Provided is an oligonucleotide which may induce an editing activity of ADRC in cell and has excellent stability in a living body. The oligonucleotide includes a first oligonucleotide identifying a target RNA and a second oligonucleotide linked to the 5?-side of the first oligonucleotide. The first oligonucleotide consists of a target-corresponding nucleotide residue, an oligonucleotide of 10 to 24 residues at the 3?-side, and an oligonucleotide of 3 to 6 residues at the 5?-side. The second oligonucleotide has no nucleotide residue corresponding to a nucleotide residue of the target RNA or has a nucleotide residue which does not form a complementary pair at the 3?-end thereof and the number of residue is 3 to 6.
    Type: Application
    Filed: December 8, 2021
    Publication date: March 21, 2024
    Applicants: FUKUOKA UNIVERSITY, DAIICHI SANKYO COMPANY, LIMITED
    Inventors: Masatora FUKUDA, Makoto KOIZUMI, Shinzo IWASHITA
  • Patent number: 11931327
    Abstract: An object of the present invention is to provide a medicine that can simply treat and/or prevent a retinal degenerative disease associated with photoreceptor degeneration, including retinitis pigmentosa. The solution is to provide an agent for treating and/or preventing a retinal degenerative disease associated with photoreceptor degeneration, containing a compound having a retinoic acid receptor agonistic activity (for example, tamibarotene, tamibarotene methyl ester, tamibarotene ethyl ester, tazarotene, tazarotenic acid, adapalene, palovarotene, retinol, isotretinoin, alitretinoin, etretinate, acitretin or bexarotene) or a salt thereof.
    Type: Grant
    Filed: July 3, 2018
    Date of Patent: March 19, 2024
    Assignee: Daiichi Sankyo Company, Limited
    Inventors: Naoki Tsuji, Masumi Ueno
  • Patent number: 11932600
    Abstract: The present invention relates to a compound or a pharmacologically acceptable salt thereof having excellent tissue non-specific alkaline phosphatase inhibitory activity. The present invention provides a compound represented by the following formula (I): wherein X1 represents a nitrogen atom or CR9, R1 represents a hydrogen atom, a C1-C6 alkyl group, or a C1-C6 alkoxy group, R2 represents a halogen atom, R3 represents a hydrogen atom or a halogen atom, R4 represents a hydrogen atom or a halogen atom, and R5 represents a C1-C3 alkylsulfonyl group, a substituted C1-C6 alkyl group, a substituted C1-C6 haloalkyl group, a substituted C1-C6 alkoxy group, or a substituted C1-C6 alkylamino group, or a pharmacologically acceptable salt thereof.
    Type: Grant
    Filed: October 22, 2019
    Date of Patent: March 19, 2024
    Assignees: Daiichi Sankyo Company Limited, Sanford Burnham Prebys Medical Discovery Institute
    Inventors: Takashi Tsuji, Yasunobu Kurosaki, Koutaro Ishibashi, Anthony B. Pinkerton
  • Publication number: 20240082418
    Abstract: A method for producing a compound represented by formula (C) wherein R1 represents an amino group protected with a protecting group, the method comprising a step of subjecting a compound represented by formula (B) wherein R1 represents the same meaning as above, to intramolecular cyclization to convert the compound into the compound represented by formula (C).
    Type: Application
    Filed: October 18, 2023
    Publication date: March 14, 2024
    Applicant: DAIICHI SANKYO COMPANY, LIMITED
    Inventors: Yoshio NISHI, Kohei SAKANISHI, Shigeru NOGUCHI, Tadahiro TAKEDA